BridgeBio Pharma stock supported by Raymond James after $300M royalty deal

BridgeBio Pharma has secured a $300 million cash infusion by selling a portion of its European acoramidis royalties to HCRx and Blue Owl, a strategic move expected to extend its financial runway into at least 2027 and mitigate cash burn and dilution risks. This funding will strengthen the company's balance sheet and support the U.S. launch of Attruby (acoramidis) and late-stage R&D programs. Following this development, multiple analysts, including Raymond James, Citi, Wolfe Research, H.C. Wainwright, and Piper Sandler, have reiterated or initiated positive ratings, citing improved financial stability and optimistic sales prospects for acoramidis.

Analysis

BridgeBio Pharma has strategically addressed a key investor concern by monetizing a portion of its future royalty stream for acoramidis, securing $300 million in non-dilutive capital. This transaction, involving the sale of 60% of its European royalties from Bayer to HCRx and Blue Owl, effectively removes a financing overhang and extends the company's operational cash runway to at least 2027. The capital infusion is earmarked to support the critical U.S. launch of Attruby (acoramidis) and advance late-stage R&D, including the Phase 3 CALIBRATE study for encaleret. The deal structure, which includes a 1.45x cap on the buyers' return, allows BridgeBio to retain long-term upside from European sales beyond that threshold. The move has been met with a strong positive consensus from the analyst community, with firms like Raymond James, Citi, and Wolfe Research affirming or initiating Outperform/Buy ratings and price targets ranging from $56 to $63, citing improved financial stability and a clear path to execute on the drug's commercialization.

Key Decisions for Investors

• This royalty monetization should be viewed as a significant de-risking event, as it secures funding through key commercial and clinical milestones, potentially warranting a re-evaluation of the stock's risk profile.
• Investors should closely monitor the execution and initial sales trajectory of the U.S. launch of Attruby, as this represents the next major catalyst and a primary use of the newly acquired capital.
• While the deal is favorable, long-term models should be adjusted to reflect the sale of 60% of the European royalty stream up to the 1.45x cap, which tempers the potential European revenue contribution in the medium term.